| Literature DB >> 25215226 |
Amanda C da Paz1, Patrícia A Bersanetti2, Marcella Q Salomão3, Renato Ambrósio4, Paulo Schor1.
Abstract
Corneal cross-linking (CXL) is increasingly performed in ophthalmology with high success rates for progressive keratoconus and other types of ectasia. Despite being an established procedure, some molecular and clinical aspects still require additional studies. This review presents a critical analysis of some established topics and others that are still controversial. In addition, this review examines new technologies and techniques (transepithelial and ultrafast CXL), uses of corneal CXL including natural products and biomolecules as CXL promoters, and evidence for in vitro and in vivo indirect effectiveness.Entities:
Year: 2014 PMID: 25215226 PMCID: PMC4151584 DOI: 10.1155/2014/890823
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
In vitro and in vivo evidences of corneal cross-linking protocols.
| Protocol |
|
|
|---|---|---|
| Epi-off CXL (Dresden Protocol) | Increased Young's modulus [ | Improvement in VA, K reading, refraction, and halt of ectasia progression |
|
| ||
| Epi-on CXL | Riboflavin penetration requires more time than with epi-off techniques | Improvement in VA and topographic findings |
|
| ||
| Ultrafast CXL | Young's modulus similar to traditional CXL [ | Equivalent in VA, refraction and pentacam parameters [ |
|
| ||
| Athens protocol | No data available | Superiorly with a better BSCVA, mean K reduction, spherical equivalent, and corneal haza score [ |